OSE Pharma : Presentation of the Future Entity OSE Immunotherapeutics at the 2nd « Annual Immuno-Oncology: BD&L and Investment Forum »

Regulatory News:

OSE Pharma SA (ISIN: FR0012127173; Ticker: OSE) (Paris:OSE) and Effimune today announce the presentation of OSE Immunotherapeutics (formed as a result of the future merger between the two companies, creating a leader in activation and regulation immunotherapy) at the « Annual Immuno-Oncology : BD&L and Investment Forum », to be held on June 3, 2016 in Chicago, in parallel to the international annual ASCO meeting (American Society of Clinical Oncology).

The goal of the Forum is to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical and biotechnology companies, and investors, with a particular focus on the field of immuno-oncology. As such, the Forum will represent an important first opportunity for the new entity, subject to and after completion of the merger, to present to various stakeholders in the US. Dominique Costantini, Chief Executive Officer of OSE Pharma, who will assume the same role upon completion of the merger, will provide an overview of OSE Immunotherapeutics, including its strategy to become a leader in the field of activation and regulation immunotherapy.

Information on the presentation of June 3, 2016:
Hyatt Chicago Magnificent Mile Hotel
Presentation track: B
Presentation time: 12 h 40

ABOUT THE 2ND ANNUAL SACHS IMMUNO-ONCOLOGY: BD&L AND INVESTMENT FORUM
The 2nd "Annual Sachs Immuno-Oncology: BD&L and Investment Forum” is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. It is expected that around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.

ABOUT THE MERGER BETWEEN OSE PHARMA AND EFFIMUNE
On February 24, 2016, OSE Pharma and Effimune announced a proposed merger to create OSE Immunotherapeutics, a significant immunotherapy player. The terms of the merger will be submitted for approval to the shareholders of the two companies during the next General Meetings: on May 30, 2016 for Effimune and on May 31, 2016 for OSE Pharma.

The objective of the merger is to create a new international enterprise that offers innovative immunotherapies based on the activation or regulation of the immune system. This new generation of products is optimized to better target key receptors of the activation or regulation of immune response and allow a durable therapeutic effect. The new company will benefit from a balanced portfolio that would open up major avenues to growth and have a financial visibility of about two years to advance its projects toward greater attractiveness.

OSE PHARMA is a biotechnology company that designs and develops cancer immunotherapy treatments aimed at re-educating the immune system to fight cancer while preserving patients’ quality of life. The Company is conducting a Phase 3 registration trial in Europe and the U.S. for its lead product, Tedopi®, in the treatment of NSCLC.

OSE Pharma is listed on Euronext Paris (ISIN: FR0012127173; Mnemo: OSE).

For more information, please visit www.osepharma.com

EFFIMUNE is a biotech company specialized in immune regulation for applications in transplantation, autoimmunity and cancer immunotherapy. The originality of Effimune’s therapeutic strategy, compared to conventional immunosuppression, is the modification in the balance between effector and regulatory immune cells. The biological drugs Effimune develops are aimed at restoring the natural balance of these cells by targeting the molecular checkpoint.

The expertise of the company lies in its ability to identify new therapeutic targets and develop effective biomolecules for the pharmaceutical industry by guaranteeing the manufacture of pilot and clinical batches and by validating preclinical and clinical proofs of concept.

For more information, please visit: www.effimune.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160512006118/en/